Noema Pharma announces publication of “Noema, Basimglurant and a New Clinical Trial for Seizures in TSC” podcast on TSC Alliance website

BASEL, Switzerland, February 22, 2022 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces that the TSC Alliance has published on its website a podcast dedicated to Basimglurant (NOE-101) and the seizures associated with tuberous sclerosis complex (TSC). The podcast is available for on-demand replay by following this link . About Noema Pharma Noema Pharma ( www.noemapharma.com ) is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche with strong safety packages. Lead product NOE-101, an mGluR5 inhibitor, is currently evaluated in Phase 2b in pain associated with Trigeminal Neuralgia (TN) and in seizures in Tuberous Sclerosis Complex (TSC). NOE-105, a PDE10A inhibitor, is in preparation for Phase 2b testing to treat Tourette Syndrome and childhood onset fluency disorders. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor. Noema Pharma was founded with the leading venture capital firms Sofinnova Partners and Polaris Partners. Investors include Gilde Healthcare, Invus and Biomed Partners. Contacts Noema Pharma Luigi Costa Chief Executive Officer [email protected] Investors & Media LifeSci Advisors – Guillaume van Renterghem [email protected] +41 (0) 76 735 01 31 Media LifeSci Advisors – Bernhard Schmid [email protected] +41 (0) 44 447 12 21

The release as fetched from its publisher. noemapharma.com ↗